scholarly journals The Effect of Various Types of Basic Therapy on Laboratory and Immunological Parameters in Ankylosing Spondylitis

2022 ◽  
Vol 8 (1) ◽  
pp. 160-168
Author(s):  
G. Kulchinova ◽  
A. Mamasaidov ◽  
A. Irisov
Keyword(s):  
Ankylosing Spondylitis ◽  
Basic Drugs ◽  
Immunological Parameters ◽  
Basic Therapy ◽  
Positive Effect ◽  
Basic Treatment

In this work examined the effect of various types of basic therapy on laboratory, including immunological parameters in ankylosing spondylitis. The influence of basic treatment of patients with ankylosing spondylitis with sulfasalazine, methotrexate and rituximab on laboratory indicators of the disease such as ESR, CRP, fibrinogen and immunological indicators such as IgM, IgG and IgA was evaluated. It has been established that all three basic drugs (sulfasalazine, methotrexate and rituximab) in ankylosing spondylitis have a positive effect on the dynamics of laboratory and immunological parameters. But at the same time, rituximab has a more pronounced and earlier effect.

scholarly journals Analysis of L-carnitine effectiveness in complex treat-ment of pregnant women with placental insufficiency

2021 ◽  
Vol 38 (5) ◽  
pp. 15-23
Author(s):  
G. H. Mamedli ◽  
G. I. Babaeva ◽  
M. E. Azizova ◽  
U. M. Sirajli ◽  
G. G. Hajizade
Keyword(s):  
Pregnant Women ◽  
Fetal Development ◽  
Placental Insufficiency ◽  
Complex Treatment ◽  
Fetal Blood ◽  
Mean Values ◽  
Treat Ment ◽  
The Mean ◽  
Positive Effect ◽  
Basic Treatment

Objective. To increase the effectiveness of treatment of placental insufficiency in pregnant women with the inclusion of L-carnitine (Inestom) in complex therapy. Materials and methods. A total of 76 pregnant women aged 18 to 39 years were examined at 2240 weeks of gestation. All the examined patients were divided into two groups. Patients of the first group (n = 37) received only basic treatment, which included the use of a complex of vasodilators, tocolytics, drugs that improve microcirculation and rheological properties of blood. Patients of the second group (n = 39) received L-carnitine along with basic therapy (Inestom, Help SA Pharmaceuticals, Greece). Results. The use of the drug Inestom as a part of the complex treatment of placental insufficiency led to the normalization of utero-placental-fetal blood flow and intrauterine fetal development in 94.7 % of pregnant women. After the course of drug therapy, there was an increase in the total score of cardiotography, which in the first group of patients was 7.08 0.06 before treatment and 7.13 0.11 after treatment (p 0.05), and in the second group 7.12 0.11 before treatment and 7.95 0.05 after (p 0.05). The results of antenatal dopplerometry showed that in pregnant women who received Inestom as a part of the complex treatment, there was a decrease in the mean values of all vascular resistance indices. Conclusions. The use of Inestom in the complex treatment of placental insufficiency has a positive effect on the state of hemodynamics in the "mother-placenta-fetus" system, and affects the intrauterine state of the fetus.

Effect of lisinopril on indicators of electrocardiographic and echocardiographic studies in patients with liver cirrosis

2021 ◽  
Vol 22 (3) ◽  
pp. 4-8
Author(s):  
V. A. Zhmurov ◽  
◽  
Yu. S. Kuzmina ◽  
T. A. Mishchenko ◽  
Yu. A. Rogozhkina ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Ace Inhibitor ◽  
Federal District ◽  
Well Being ◽  
Cirrhosis Of The Liver ◽  
Qtc Interval ◽  
Shortness Of Breath ◽  
Basic Drugs ◽  
Siberian Federal District ◽  
Basic Therapy

Chronic diffuse liver diseases (CDLD) of various etiologies remain a serious socio-economic and clinical-epidemiological health problem. Every year more than 1 million people die from cirrhosis of the liver of various etiology all over the world. According to the results of a study by a group of authors, it was found that in the Siberian Federal District there is an unfavorable situation in terms of gastroenterological mortality, in particular, hepatological mortality. CCM is characterized by lengthening of the QT interval, electromechanical dyssynchronization, and chronotropic insufficiency. The duration of the QTc interval in the subgroup of patients with liver cirrhosis who received basic therapy and the drug lisinopril (Diroton) was (418.21 ± 2.74 ms) and was significantly lower than in the subgroup of patients receiving only basic therapy. Evaluating the parameters of transthoracic echocardiography among patients with liver cirrhosis, it was noted that during treatment with basic drugs in combination with lisinopril (Diroton), the volume of LV EDV significantly decreased (p < 0.05). The appointment of an ACE inhibitor lisinopril to patients with cirrhosis of the liver as part of complex therapy leads to an improvement in general well-being, a decrease in shortness of breath, an increase in exercise tolerance, an improvement in basic laboratory parameters, as well as an improvement in some morphometric parameters (EDV) and cardiac electrical systole.

Study of the effect of menopausal hormone therapy in women with psoriasis type 2 in postmenopause

2016 ◽  
Vol 19 (5) ◽  
pp. 296-300
Author(s):  
Evgeniya P. Opruzhenkova ◽  
O. A Sidorenko ◽  
L. A Anisimova ◽  
V. V Starostenko
Keyword(s):  
Hormone Therapy ◽  
Clinical Manifestations ◽  
Menopausal Hormone Therapy ◽  
Control Group ◽  
Study Group ◽  
Hormonal Status ◽  
Basic Therapy ◽  
Basic Treatment

The results of comparative analysis of the hormonal status from 75 women aged from 49 to 60 years old (average age 54.04 ± 1.28 year) in postmenopause with psoriasis type 2 (study group) and 50 women of control group of the same age and menstrual status without psoriasis are presented. There were two subgroups in the main group: subgroup 1 received basic therapy in combination with menopausal hormone therapy (MHT) (estradiol 1 mg + drospirenone 2 mg), subgroup 2 - basic therapy. Psoriatic process was assessed according to PASI index and was evaluated by the dermatology quality of the life index (DIQL) and the content of gonadotropic and sex hormones before treatment and after 3 and 6 months of starting treatment in patients of both subgroups. More pronounced clinical efficacy in combination with reduced FSH level is 13.2% (p < 0.001), increased content of estradiol 69.3% (p < 0.001) was observed in patients from 1 subgroup. MHT supplement to the basic treatment decreased the PASI index after 3 months of starting treatment for 50.9% (p fter 6 months - at 94% (p < 0.001), and reduced DIQL in subgroup 1 compared to 2 subgroup after 3 months - 15.3% (p < 0.05) and after 6 months - 20.8% (p < 0.05). In postmenopausal women with psoriasis favorable changes of indexes reflecting the clinical manifestations of the disease were associated with the correction of hormonal status in MHT estradiol 1 mg + drospirenone 2 mg.

scholarly journals Ankylosing spondylitis in monozygotic twins: studies on immunological parameters

1999 ◽  
Vol 58 (7) ◽  
pp. 435-440 ◽  
Author(s):  
T. Hohler ◽  
R. Hug ◽  
P. M Schneider ◽  
F. Krummenauer ◽  
C. Gripenberg-Lerche ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Monozygotic Twins ◽  
Immunological Parameters

scholarly journals The Possibilities of Using Fruit Waste in Nutrition of Poultry

2019 ◽  
Vol 7 (5) ◽  
pp. 724
Author(s):  
Ahmet Yusuf Şengül ◽  
Ömer Şengül ◽  
Aydın Daş
Keyword(s):  
Nutritional Value ◽  
Fruit Juice ◽  
Natural Antioxidant ◽  
Feed Additive ◽  
Human Consumption ◽  
Immunological Parameters ◽  
Fruit Waste ◽  
Fruit Wastes ◽  
Poultry Feeding ◽  
Positive Effect

Particularly in the fruit juice industry, the remaining peels and pulp parts are not available for human consumption after the juices are used. It is possible to evaluate these wastes by adding them to poultry feeds. A number of studies have been conducted by researchers on the nutritional value of many fruit wastes and on the performance of poultry. Natural antioxidant content has been reported to have a positive effect on growth, microbial and immunological parameters when high fruit peels are used as feed additive in poultry feeding.

scholarly journals The application experience of terahertz radiation for osteoarthritis of the knee

2020 ◽  
Vol 17 (3) ◽  
pp. 145-148
Author(s):  
A. G. Kulikov ◽  
Anna Ivanovna Ageeva ◽  
S. A. Volovets
Keyword(s):  
Terahertz Radiation ◽  
Ceramic Coating ◽  
Clinical Symptoms ◽  
Disease Type ◽  
Knee Joints ◽  
Favorable Effect ◽  
Osteoarthritis Of The Knee ◽  
Methods Of Treatment ◽  
Positive Effect ◽  
Basic Treatment

The aim of this work was to increase the effectiveness of treatment in patients with osteoarthritis of the knee by including in the treatment complex procedures of electromagnetic radiation of the terahertz range. This study was prospective and randomized. 65 patients were examined and treated. They were divided into 2 groups comparable to sex, age, disease type, and severity. All patients received basic therapy, including drugs and exercise therapy. In addition to the basic treatment, the patients of the main group underwent a course of terahertz therapy using the Emir device with a ceramic coating of the emitter. The study revealed that the procedures of terahertz therapy are well tolerated by patients, do not cause exacerbation and are combined with other methods of treatment of gonarthrosis. Repeated studies at the end of the course of treatment showed that the inclusion of terahertz radiation in the therapeutic complex has a positive effect on the main clinical symptoms of the disease, reducing the intensity of pain in the knee joints and improving their functional state, having a favorable effect on the state of local hemodynamics.

scholarly journals The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Kui Zhang ◽  
Yan Zheng ◽  
Qing Han ◽  
Ying Liu ◽  
Weitao Wang ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Activity Index ◽  
Group Versus ◽  
Quantitative Mri ◽  
Harris Hip Score ◽  
Control Group ◽  
Hip Arthritis ◽  
Tnf Α ◽  
Basic Treatment

ObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.MethodsA total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-α inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).ResultsThe clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p &lt; 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-α inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-α inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 ± 10.37 vs. 20.59 ± 9.41, p &lt; 0.001); the control group only had slight improvement (p &lt; 0.05).ConclusionsTNF-α inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-α in SpA patients with hip involvement to help guide targeted treatment.

ВАРИАБЕЛЬНОСТЬ ОТВЕТА НА СТАНДАРТНУЮ ФАРМАКОТЕРАПИЮ У ПАЦИЕНТОВ С БРОНХИАЛЬНОЙ АСТМОЙ

2019 ◽  
Author(s):  
K.S. Pavlova ◽  
D.S. Mdinaradze ◽  
O.M. Kurbacheva
Keyword(s):  
Ipratropium Bromide ◽  
Tiotropium Bromide ◽  
Bronchial Obstruction ◽  
Asthma Phenotype ◽  
Basic Therapy ◽  
Asthma Symptoms ◽  
Asthma Patients ◽  
High Doses ◽  
Long Acting ◽  
Basic Treatment

Актуальность. Основанием для проведения данного исследования послужило наличие группы пациентов с бронхиальной астмой (БА), которые предпочитают для купирования приступов удушья использовать короткодействующие антихолинергические препараты (КДХП). Цель. Изучение возможной низкой эффективности длительно действующих Р2-агонистов (ДДБА) у пациентов с БА, не имеющих достаточного ответа на КДБА, а также вероятности уменьшения бронхиальной обструкции с помощью длительно действующих антихолинергических препаратов (ДДХП) у этих пациентов. Материалы и методы. В исследовании приняли участие 12 взрослых некурящих пациентов с БА средней степени тяжести (III-IV ступень по GINA), получавшие в качестве базисной терапии ИГКС в средних или высоких дозах в сочетании с ДДБА, при этом характеризовались отсутствием или неполным контролем над симптомами БА. В первую (n7) группу были определены пациенты с клинически и инструментально подтвержденной эффективностью сальбутамола, которые в то же время имели хороший ответ на ипратропия бромид (КДБАКДХП). Во вторую группу (n5) вошли пациенты с низким ответом на саль-бутамол и положительным тестом с ипратропия бромидом (КДБА-КДХП). Пациентам проводили серию исследований функции внешнего дыхания (ФВД) до и через 5, 10, 15, 30, 60, 120 и 240 мин после ингаляции бронхолитического средства (салметерола 50 мкг, формотерола 12 мкг и тиотропия бромида 18 мкг). Результаты. Было показано, что пациенты с БА и фенотипом КДБА-КДХП имеют низкий ответ на ДДБА: максимальный прирост ОФВгпосле ингаляции сальметерола составил 7,641,67 и 156,0116,03 мл, а после формотерола 9,435,84, 166,71103,14 мл (в сравнении с группой КДБАКДХП, где ответ на сальметерол составил 20,812,42 и 551,4393,94 мл, а на формотерол 30,216,75 и 718,57140,78 мл), и хороший ответ на ДДХП (13,735,78 и 250,0361,61). Заключение. Результаты исследования дают основание к выделению отдельного фенотипа БА с низкой обратимостью бронхиальной обструкции в ответ на КДБА и достаточной обратимостью в ответ на КДХП (КДБА-КДХП). Этой группе пациентов в качестве базисной терапии следует рассматривать сочетание ИГКСДДБА и ДДХП (тиотропия бромида).Background. The aim of this study was to analyse the group of patients with asthma, who prefer to use short-acting anticholinergics (SAMA) for relief of asthma attacks. At the same time, these patients are prescribed inhaled glucocorticosteroids (ICS) in combination with long-acting P2-agonists (LABA) as a basic therapy according to the standards. Tha aim. To study the cause of low efficacy of LABA in patients with asthma who do not have a sufficient response to SABA, as well as the probability of reducing of bronchial obstruction with LAMA. Materials and methods. 12 non-smoking adults with moderate to severe asthma (III-IV stage of GINA), receiving medium or high doses of ICS in combination with LABA as a basic therapy without adequate control over asthma symptoms were included in the study. First group of patients showed the efficacy of salbutamol (FEV1reversibility was more than 12 and more than 200 ml after 400 g of salbutamol) and ipratropium bromide (SABASAMA). Second group included patients with low response to salbutamol and positive test (FEVtreversibility) with ipratropium bromide (SABA-SAMA). Spirometry was performed at baseline point and in 5, 10, 15, 30, 60, 120 and 240 min after inhalation of bronchodilator (salmeterol 50 g, formoterol 12 g and tiotropium bromide 18 g in the different days). Results. It was shown that SABA-SAMA phenotype asthma patients demonstrated low response to LABA: FEV1increased up to 7.641.67, 156.016.0 ml after salmeterol inhalation and up to 9.45.8, 166.7103.1 ml after formoterol inhalation (compared with a group of SABASAMA, where the response to salmeterol was 20.812.42, 551.4393.94 ml and the response to formoterol was 30.216.75, 718.57140.78 ml, p0.05), and a good response to LAMA (13.75.8 and 250.061.6). Conclusion. The results of the study allowed to define asthma phenotype with low bronchial obstruction reversibility to SABA and sufficient reversibility to SAMA (SABA-SAMA). This group of asthma patients need the basic treatment with the combination of ICS and LABA and LAMA (tiotropium bromide).

scholarly journals Levels of cytokines in extended purulent peritonitis and methods of immunocorrection

2020 ◽  
Vol 87 (11-12) ◽  
pp. 54-61
Author(s):  
E. T. Mammadova
Keyword(s):  
Inflammatory Cytokines ◽  
Proinflammatory Cytokines ◽  
Basic Therapy ◽  
Tnf Α ◽  
Purulent Peritonitis ◽  
Treatment Measures ◽  
Healthy Persons ◽  
Basic Treatment ◽  
Cytokines Secretion ◽  
Severity Degree

Objective. Comparative studying of the cytokines secretion dynamics in extended purulent peritonitis in postoperative period on background of the standard basic therapy and its combination with cytokinotherapy. Materials and methods. The levels of anti-inflammatory cytokines IL-2, IL-6, IL-8 and TNF-α in the blood of 97 patients, suffering extended purulent peritonitis of various genesis and various severity degree, were determined. Depending on kind of therapy conducted, the patients were divided into two Groups: the first one - 52 patients, obtaining standard basic therapy and the second - 45 patients, to whom cytokinotherapy was prescribed additionally to standard basic therapy. Results. In the Group II patients the levels of IL-2, IL-6, IL-8 and TNF-α were raised significantly in reactive phase in 2.1 (p=0.035), 2.4 (p=0.002), 2.0 (p=0.004) and 3.5 (p=0.001) times, accordingly; toxic - in 5.1 (p<0.001), 5.6 (p<0.001), 2.4 (p<0.001) and 6.6 (p<0.001) times, accordingly; terminal - in 8.7 (p<0.001), 8.7 (p<0.001), 4.7 (p<0.001) and 8.6 (p<0.001) times, accordingly, comparing with control. On the tenth postoperative day the concentration of proinflammatory cytokines have lowered significantly in comparison to preoperative data. Conclusion. In all the patients, owing various degrees of the extended purulent peritonitis severity, preoperatively a statistically significant raise of concentration of proinflammatory cytokines IL-2, IL-6, IL-8 and TNF-­α, comparing with indices in healthy persons, was noted. Targeted immunocorrection, using combined cytokinotherapy on background of complex basic treatment measures, normalizes a cytokinic balance.

scholarly journals Program «Smart ECG – ranolazin» - own experience and world approach

2020 ◽  
Vol 24 (4 (96)) ◽  
pp. 110-116
Author(s):  
V. Tashchuk ◽  
O. Malinevska-Biliichuk ◽  
D. Onofreichuk ◽  
P. Ivanchuk ◽  
M. Tashchuk
Keyword(s):  
Clinical Trials ◽  
Exercise Tolerance ◽  
Control Group ◽  
Level Of Evidence ◽  
Aldosterone Antagonists ◽  
Basic Therapy ◽  
Group I ◽  
Improve Exercise Tolerance ◽  
Angina Frequency ◽  
Positive Effect

Purpose - comprehensive analysis of the world approach of the use of ranolazine in various clinical trials and the introduction of the program "Smart ECG" to assess the effectiveness of ranolazine.Matherial and methods. Evaluation of European guidelines, analysis of global randomized clinical trials of the ranolazine use, presentation of our own trial: we examined 40 patients with Q wave myocardial infarction (STEMI), were instituted basic therapy according to the modern recommendations which contained interventional treatment with restoration of patency of a heart attack-conditioned coronary artery, double antiplatelet therapy, statins, β-adrenergic blocker, angiotensin-converting enzyme inhibitors, aldosterone antagonists with addition of ranolazine (group I, 30 patients diagnosed STEMI), control - group II, 10 patients with STEMI, who received basic therapy without addition of ranolazine. Results. Analysis of clinical trials (CARISA, MARISA, ERICA, TERISA, MERLIN-TIMI, RIVER-PCI, RIMINI-TRIAL) proved the effectiveness of ranolazine as an antianginal and anti-ischemic drugs. The use of own program «Smart ECG» demonstrates the positive effect of ranolazine on STEMI and requires further implementation.Conclusion. In the European Society of Cardiology guidelines of the management of stable angina pectoris, ranolazine is given a class IIa (level of evidence B) recommendation as a second-line treatment to reduce angina frequency and improve exercise tolerance in subjects who cannot tolerate, have contraindications to, or whose symptoms are not adequately controlled by β- adrenergic blockers, calcium channel blockers and long-acting nitrates. In subjects with baseline low heart rate and low blood pressure, ranolazine may be considered as a first-line drug to reduce angina frequency and improve exercise tolerance - class IIa (level of evidence C) recommendation. Own study, which partially reflects the global approach according to the analyzed clinical studies, demonstrates the positive effect of ranolazine for patients with STEMI - analogue scale EQ–VAS indicates a positive effect, positive influence on the markers of electrical myocardial instability: decreasing of the probability of cases of SDNN decrease, depression of QT and maybe increase of ratio of maximum velocity for differentiated T wave.

Sign in / Sign up

Export Citation Format

Share Document